Prix Ascletis Pharma Inc (01672.HK)

Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang and currently employs 208 full-time employees. The company went IPO on 2018-08-01. The firm focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The firm's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The firm conducts its business in the domestic and overseas markets.